Last reviewed · How we verify
Intravenous deferiprone
At a glance
| Generic name | Intravenous deferiprone |
|---|---|
| Also known as | IV DFP, Deferiprone injection, solution |
| Sponsor | ApoPharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases (PHASE2)
- Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects (PHASE1)
- A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous deferiprone CI brief — competitive landscape report
- Intravenous deferiprone updates RSS · CI watch RSS
- ApoPharma portfolio CI